The Numbers Got Worse

GLP-1 drugs were already reshaping consumer behavior — grocery bills, clothing purchases, the whole downstream economy. Two major studies published in 2026 now quantify the surgical collapse with hard numbers.

A study published in JAMA Surgery — analyzed by Medical Xpress on May 21, 2026 — examined weight-loss treatment data from 11.7 million anonymous insurance enrollees diagnosed with obesity, overweight, or diabetes. GLP-1 drug use surged 140.4% between 2022 and 2024. In the same window, metabolic bariatric surgery (MBS) utilization dropped 34.1%.

One-third of the bariatric surgery market disappeared in two years.

The Earlier Data Already Flashed a Warning

This pattern emerged earlier. A prior study published in JAMA Network Open, covered by STAT News on October 25, 2024, looked at health records of 17 million privately insured Americans with obesity. Between 2022 and 2023 alone — just one year — bariatric surgery rates fell 8.7% while GLP-1 prescriptions more than doubled.

Thomas Tsai, the lead author of that study and a bariatric surgeon at Brigham and Women's Hospital in Boston who also holds positions at Harvard Medical School and the T.H. Chan School of Public Health, observed a shift in his own practice. He noticed an uptick in last-minute surgery cancellations from patients who had recently started GLP-1 medications. He wanted to know if it was a national pattern. It was.

"On a population level, among a subset of commercially insured individuals, that is the tradeoff that is happening," Tsai told STAT News.

Bariatric surgery volumes had been climbing steadily for a decade — from 158,000 procedures in 2011 to 280,000 in 2022, according to the American Society for Metabolic and Bariatric Surgery. That 2022 peak was partly a Covid-era rebound from paused elective surgeries. Then GLP-1s hit scale, and the trend reversed.

What Mainstream Coverage Is Missing

Most health media frames this as a "patients have options now" story. The fuller picture is more complex.

First, the hospital revenue question deserves direct acknowledgment. According to STAT News, Marc Bessler — chair of surgery at Northwell Lenox Hill Hospital in New York City and CEO of EndObetes — acknowledged the obvious: clinics that built significant revenue streams around bariatric procedures now face an uncertain future. This represents serious economic disruption to health systems.

Second, the insurance economics matter. GLP-1 drugs like Wegovy and Zepbound are expensive — often $1,000 or more per month before discounts. Bariatric surgery is a one-time cost. The 140.4% surge in GLP-1 prescriptions means insurers are now covering recurring drug costs at massive scale instead of one-time surgical costs. Over a decade, employer-sponsored health plans will see significant cost differences.

Third, efficacy comparisons are incomplete. Healthline's coverage of the bariatric-vs-GLP-1 debate notes that surgery still produces greater long-term weight loss for most patients. Gastric bypass and gastric sleeve procedures physically restructure the stomach. GLP-1 drugs work as long as you take them — stop the drug, and weight often returns. Surgery's results are durable.

The Biology Is Simple, the Policy Isn't

GLP-1 drugs — including liraglutide, semaglutide (Ozempic, Wegovy), and tirzepatide (Zepbound) — mimic a gut hormone that slows stomach emptying and signals fullness, according to Medical Xpress. They're genuinely effective. The 2026 JAMA Surgery data doesn't dispute that.

But "effective" and "better for everyone" are not the same thing. A patient who cannot afford a lifetime of drug costs, or whose insurance coverage changes, may have been better served by a one-time surgical intervention. Working-class patients facing these tradeoffs deserve equal consideration in the public conversation.

What Comes Next

The drugs work. The disruption is real. The full cost — to patients, hospitals, and insurers — is still being counted. Hospital bariatric programs face a 34.1% decline in two years. The industry will need to adapt.